share_log

榮昌生物：建議發行A股

REMEGEN: PROPOSED ISSUANCE OF A SHARES

香港交易所 ·  Apr 1 06:36
Summary by Moomoo AI
榮昌生物製藥（煙台）股份有限公司（「榮昌生物」）於2024年3月29日宣布，董事會已通過決議案，建議在一般授權限額內向不超過35名特定對象發行不超過70,763,170股A股，預計籌集不超過人民幣2,550百萬元。該建議發行需獲股東於臨時股東大會批准，並須通過上海證券交易所審核及中國證監會同意註冊。建議發行的特定對象包括符合中國證監會規定條件的投資者，並將以人民幣現金方式以同一價格認購。所得款項淨額將用於新藥研發項目。建議發行完成後，特定對象所認購的股份將受六個月禁售期限制。榮昌生物表示，此次籌資將加快公司創新藥物的研發進程，增強臨床前研究與臨床研究的協同性，並提高公司的資本實力及抗風險能力。
榮昌生物製藥（煙台）股份有限公司（「榮昌生物」）於2024年3月29日宣布，董事會已通過決議案，建議在一般授權限額內向不超過35名特定對象發行不超過70,763,170股A股，預計籌集不超過人民幣2,550百萬元。該建議發行需獲股東於臨時股東大會批准，並須通過上海證券交易所審核及中國證監會同意註冊。建議發行的特定對象包括符合中國證監會規定條件的投資者，並將以人民幣現金方式以同一價格認購。所得款項淨額將用於新藥研發項目。建議發行完成後，特定對象所認購的股份將受六個月禁售期限制。榮昌生物表示，此次籌資將加快公司創新藥物的研發進程，增強臨床前研究與臨床研究的協同性，並提高公司的資本實力及抗風險能力。
Wing Cheong Biopharmaceuticals (Yantai) Co., Ltd. (“Wing Cheong Biologics”) announced on 29 March 2024 that its Board of Directors has adopted a resolution proposing to issue no more than 70,763,170 shares of A-shares to no more than 35 specific entities within the general authorization limit, with an expected raising of not more than RMB2,550 million. The proposed issuance is subject to shareholder approval at the Extraordinary General Meeting and subject to approval by the Shanghai Stock Exchange and registration with the approval of the China Securities and Exchange Commission. The specific target audience of the proposed issue includes investors who meet China Securities Regulatory Commission requirements and will subscribe for the same price in RMB cash. The net proceeds will be used for new...Show More
Wing Cheong Biopharmaceuticals (Yantai) Co., Ltd. (“Wing Cheong Biologics”) announced on 29 March 2024 that its Board of Directors has adopted a resolution proposing to issue no more than 70,763,170 shares of A-shares to no more than 35 specific entities within the general authorization limit, with an expected raising of not more than RMB2,550 million. The proposed issuance is subject to shareholder approval at the Extraordinary General Meeting and subject to approval by the Shanghai Stock Exchange and registration with the approval of the China Securities and Exchange Commission. The specific target audience of the proposed issue includes investors who meet China Securities Regulatory Commission requirements and will subscribe for the same price in RMB cash. The net proceeds will be used for new drug development projects. Upon completion of the proposed issuance, shares subscribed for by specific entities will be subject to a six-month grace period. Wing Cheong Bios said the funding will accelerate the company's R&D process for innovative drugs, enhance synergies between pre-clinical and clinical research, and enhance the company's capital strength and risk resilience.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more